Literature DB >> 14568926

CD8+ alpha beta+ T cells that lack surface CD5 antigen expression are a major lymphotactin (XCL1) source in peripheral blood lymphocytes.

Laura Stievano1, Valeria Tosello, Novella Marcato, Antonio Rosato, Annalisa Sebelin, Luigi Chieco-Bianchi, Alberto Amadori.   

Abstract

To better characterize the cellular source of lymphotactin (XCL1), we compared XCL1 expression in different lymphocyte subsets by real-time PCR. XCL1 was constitutively expressed in both PBMC and CD4(+) cells, but its expression was almost 2 log higher in CD8(+) cells. In vitro activation was associated with a substantial increase in XCL1 expression in both PBMC and CD8(+) cells, but not in CD4(+) lymphocytes. The preferential expression of XCL1 in CD8(+) cells was confirmed by measuring XCL1 production in culture supernatants, and a good correlation was found between figures obtained by real-time PCR and XCL1 contents. XCL1 expression was mostly confined to a CD3(+)CD8(+) subset not expressing CD5, where XCL1 expression equaled that shown by gammadelta(+) T cells. Compared with the CD5(+) counterpart, CD3(+)CD8(+)CD5(-) cells, which did not express CD5 following in vitro activation, showed preferential expression of the alphaalpha form of CD8 and a lower expression of molecules associated with a noncommitted/naive phenotype, such as CD62L. CD3(+)CD8(+)CD5(-) cells also expressed higher levels of the XCL1 receptor; in addition, although not differing from CD3(+)CD8(+)CD5(+) cells in terms of the expression of most alpha- and beta-chemokines, they showed higher expression of CCL3/macrophage inflammatory protein-1alpha. These data show that TCR alphabeta-expressing lymphocytes that lack CD5 expression are a major XCL1 source, and that the contribution to its synthesis by different TCR alphabeta-expressing T cell subsets, namely CD4(+) lymphocytes, is negligible. In addition, they point to the CD3(+)CD8(+)CD5(-) population as a particular T cell subset within the CD8(+) compartment, whose functional properties deserve further attention.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14568926     DOI: 10.4049/jimmunol.171.9.4528

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Gene expression profiles of T lymphocytes are sensitive to the influence of heavy smoking: A pilot study.

Authors:  Petra Büttner; Sandy Mosig; Harald Funke
Journal:  Immunogenetics       Date:  2006-12-06       Impact factor: 2.846

2.  Expressions of lymphotactin and its receptor, XCR, in Lewis rats with experimental autoimmune anterior uveitis.

Authors:  Po-Ting Yeh; Feng-An Lin; Chang-Pin Lin; Chung-May Yang; Muh-Shy Chen; Chang-Hao Yang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-06-29       Impact factor: 3.117

3.  Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4.

Authors:  Valeria Tosello; Rita Zamarchi; Anna Merlo; Margherita Gorza; Erich Piovan; Susanna Mandruzzato; Vincenzo Bronte; Xinhui Wang; Soldano Ferrone; Alberto Amadori; Paola Zanovello
Journal:  Eur J Immunol       Date:  2009-01       Impact factor: 5.532

4.  T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity.

Authors:  Adrienne Verhoef; Clare Alexander; A Barry Kay; Mark Larché
Journal:  PLoS Med       Date:  2005-03-29       Impact factor: 11.069

Review 5.  International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.

Authors:  Francoise Bachelerie; Adit Ben-Baruch; Amanda M Burkhardt; Christophe Combadiere; Joshua M Farber; Gerard J Graham; Richard Horuk; Alexander Hovard Sparre-Ulrich; Massimo Locati; Andrew D Luster; Alberto Mantovani; Kouji Matsushima; Philip M Murphy; Robert Nibbs; Hisayuki Nomiyama; Christine A Power; Amanda E I Proudfoot; Mette M Rosenkilde; Antal Rot; Silvano Sozzani; Marcus Thelen; Osamu Yoshie; Albert Zlotnik
Journal:  Pharmacol Rev       Date:  2013-11-11       Impact factor: 25.468

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.